<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100893</url>
  </required_header>
  <id_info>
    <org_study_id>03178</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-IRB-03178</secondary_id>
    <secondary_id>CDR0000407637</secondary_id>
    <nct_id>NCT00100893</nct_id>
  </id_info>
  <brief_title>IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer</brief_title>
  <official_title>A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,&#xD;
      or coming back. The use of IH636 grape seed extract may prevent breast cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of IH636 grape seed&#xD;
      extract in preventing breast cancer in postmenopausal women at risk of developing breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of IH636 grape seed proanthocyanidin extract, in terms of&#xD;
           suppression of estrogen biosynthesis, in healthy post-menopausal women at high risk of&#xD;
           developing breast cancer.&#xD;
&#xD;
        -  Determine the safety and tolerability of this dietary supplement, in terms of symptoms&#xD;
           and changes in markers of bone and lipid metabolism and in markers of nonspecific&#xD;
           adrenal suppression, in these participants.&#xD;
&#xD;
        -  Determine, preliminarily, an optimum biologic dose of this dietary supplement, as&#xD;
           defined by suppression of serum estradiol, in these participants.&#xD;
&#xD;
        -  Determine a minimum duration of use of this dietary supplement to achieve aromatase&#xD;
           inhibition in these participants.&#xD;
&#xD;
      OUTLINE: This is a pilot, dose-finding, placebo-controlled study.&#xD;
&#xD;
      Participants receive oral placebo once or twice daily on days -14 to 0. Participants then&#xD;
      receive oral IH636 grape seed proanthocyanidin extract once or twice daily on days 1-85.&#xD;
      Treatment continues in the absence of toxicity.&#xD;
&#xD;
      Cohorts of 6 participants receive one of four dose levels of IH636 grape seed&#xD;
      proanthocyanidin extract up to an established safe dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 participants will be accrued for this study within 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estrogen suppression as measured by serum estradiol, estrone, estrone sulfate, and sex hormone binding globulin</measure>
    <time_frame>at 1, 2, 4, 8, and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Androgenic effects as measured by serum testosterone, androstenedione, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS)</measure>
    <time_frame>at 1, 2, 4, 8, and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid effects as measured by total cholesterol, LDL, HDL, and triglycerides</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone metabolic effects as measured by bone-specific alkaline phosphatase and N-telopeptides</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin regulatory effects as measured by insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFBP3)</measure>
    <time_frame>at 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics as measured by procyanidins</measure>
    <time_frame>before and after first dose and then at 1, 2, 4, 8, and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dietary Supplement: grape seed proanthocyanidin extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IH636 grape seed proanthocyanidin extract</intervention_name>
    <description>Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage</description>
    <arm_group_label>Dietary Supplement: grape seed proanthocyanidin extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  At risk of developing breast cancer&#xD;
&#xD;
          -  No history of breast cancer or ductal carcinoma in situ&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  40 to 75&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Postmenopausal, defined by 1 of the following criteria:&#xD;
&#xD;
               -  No spontaneous menses for ≥ 12 months&#xD;
&#xD;
               -  Prior bilateral oophorectomy&#xD;
&#xD;
               -  Prior hysterectomy with follicle-stimulating hormone within menopausal range&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,500/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No major illness of the cardiovascular system&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No major illness of the respiratory system&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No history of other invasive cancer within the past 5 years except squamous cell or&#xD;
             basal cell skin cancer&#xD;
&#xD;
          -  No major systemic infection&#xD;
&#xD;
          -  No Cushing's syndrome or adrenal insufficiency&#xD;
&#xD;
          -  No osteoporosis, defined as a bone mineral density T-score ≥ -2.5 on dual-energy x-ray&#xD;
             absorptiometry scan (calcium and/or cholecalciferol [vitamin D] supplementation AND/OR&#xD;
             bisphosphonate therapy allowed provided participant is on a stable dose during study&#xD;
             participation)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 3 months since prior hormone-modifying medications, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Oral contraceptives&#xD;
&#xD;
               -  Hormone replacement therapy&#xD;
&#xD;
               -  Selective estrogen receptor modifiers&#xD;
&#xD;
               -  Aromatase inhibitors&#xD;
&#xD;
               -  Gonadotropin-releasing hormone modifiers&#xD;
&#xD;
          -  Concurrent dehydroepiandrosterone (DHEA) allowed, provided dose remains constant&#xD;
             during study participation&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No red wine, red grapes, or white button mushrooms directly before or during study&#xD;
             treatment&#xD;
&#xD;
               -  White and seedless grapes allowed&#xD;
&#xD;
          -  No other concurrent therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>January 6, 2005</study_first_submitted>
  <study_first_submitted_qc>January 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2005</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proanthocyanidin</mesh_term>
    <mesh_term>Procyanidin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

